In addition, HR+/HER2- BC patients with gBRCA1/2m administered olaparib + paclitaxel achieved 67% (10/15 patients) pCR, whereas no BRCA1/2 WT HR+/HER2- BC patients (0/4 patients) achieved pCR, demonstrating that PARPis exhibited marked antitumor effects in this subgroup [86]. This evidence concerns the gene ERBB2 and breast cancer.